mda-9/syntenin promoter to image and treat metastatic cancer cells
US9701985B2 · kind B2 · utility
0Cited by
20References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 4, 2014 |
| Grant date | Jul 11, 2017 |
| Priority date | — |
| Expiry date | Jun 4, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2830/85
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Recombinant vectors in which expression of one or more elements (e.g. gene required for viral replication, detectable imaging agents, therapeutic agents, etc.) is driven by an mda-9/syntenin (mda-9) cancer selective promoter are provided, as are cells and transgenic animals that contain such vectors. The vectors are used in cancer therapy and/or diagnostics, especially to visualize (image) and treat metastasis (including in rapid in vitro assays), and the transgenic mice are used to monitor cancer progression and/or the efficacy of candidate therapeutic agents in screening assays.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.